The Australia Continuous Glucose Monitoring Devices Market size is estimated at USD 141.96 million in 2024, and is expected to reach USD 247.96 million by 2029, growing at a CAGR of 11.80% during the forecast period (2024-2029).
The onset of the COVID–19 pandemic has significantly impacted the Australian health system, including mortality, hospitalizations, health services, disease management, and surveillance. Diabetes is one of many conditions correlated with greater health consequences throughout the COVID-19 pandemic, including increased risk of complication and mortality. Some studies have proposed a link between COVID-19, hyperglycemia, and new-onset diabetes.
The Australian government simplified the clinical eligibility criteria for the Continuous Glucose Monitoring (CGM) Initiative in March 2020, which allowed people with type 1 diabetes under the age of 21 and those over the age of 21 with valid concessional status to access fully subsidized CGM devices through the National Diabetes Services Scheme.
Continuous Glucose Monitoring is a device that reads the glucose level between the cells underneath the skin. The device consists of a sensor and a transmitter. The continuous glucose reading can be sent to a receiver, smartphone app, or insulin pump. According to the Australian Institute of Health and Welfare, Type 1 diabetes accounts for around 10–15% of people with diabetes. It is one of the most serious and common chronic diseases of childhood, with about half of the people with Type 1 diabetes developing the disease before age 18.
The growing demand for blood glucose monitoring devices and increasing support initiatives such as NDSS are expected to increase product penetration and drive the market studied during the forecast period.
The receiver shows glucose values. A standalone, compatible smartphone or other smart device can be the receiver. The receiver also stores data on glucose. For a review by the patient and their diabetes health provider, the patient can upload the glucose data. Making judgments regarding adjustments to their insulin dosages or insulin pump settings using this information will help. Australia has one of the highest incidence rates of Type 1 Diabetes in children, ranking 16th out of 123 countries globally for incidences of Type 1 Diabetes in children. All the initiatives from the Australian government encourage the Continuous Glucose Monitoring Durables market to increase in the forecast period.
Currently, almost 1.9 million Australians have diabetes, including all types of diagnosed diabetes (almost 1.5 million known and registered) and undiagnosed type 2 diabetes (up to 500,000 estimated). Around 1.2 million people are hospitalized with diabetes-related conditions every year. Aboriginal and Torres Strait Islander Australians are three times more likely to develop type 2 diabetes than non-indigenous Australians, 4.3 times more likely to be hospitalized with type 2 diabetes, and four times as likely to die from it.
Overall, with rising diabetes prevalence, access to CGM and Flash GM through the NDSS assists in the reduction of the number of severe hypoglycemic events, improvement of glucose management in people with poor glycemic awareness or suboptimal glycemic control (maintaining blood glucose levels in the target range reduces the risks of developing diabetes-related complications) thereby driving the market growth.
This product will be delivered within 2 business days.
The onset of the COVID–19 pandemic has significantly impacted the Australian health system, including mortality, hospitalizations, health services, disease management, and surveillance. Diabetes is one of many conditions correlated with greater health consequences throughout the COVID-19 pandemic, including increased risk of complication and mortality. Some studies have proposed a link between COVID-19, hyperglycemia, and new-onset diabetes.
The Australian government simplified the clinical eligibility criteria for the Continuous Glucose Monitoring (CGM) Initiative in March 2020, which allowed people with type 1 diabetes under the age of 21 and those over the age of 21 with valid concessional status to access fully subsidized CGM devices through the National Diabetes Services Scheme.
Continuous Glucose Monitoring is a device that reads the glucose level between the cells underneath the skin. The device consists of a sensor and a transmitter. The continuous glucose reading can be sent to a receiver, smartphone app, or insulin pump. According to the Australian Institute of Health and Welfare, Type 1 diabetes accounts for around 10–15% of people with diabetes. It is one of the most serious and common chronic diseases of childhood, with about half of the people with Type 1 diabetes developing the disease before age 18.
The growing demand for blood glucose monitoring devices and increasing support initiatives such as NDSS are expected to increase product penetration and drive the market studied during the forecast period.
Australia Continuous Glucose Monitoring Devices Market Trends
The Durables Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period
A wireless receiver, insulin pump, compatible smartphone, or smart device receives glucose readings from the sensor coupled to the transmitter. Depending on the type, a transmitter must be replaced every three to twelve months. Transmitters cannot be used again.The receiver shows glucose values. A standalone, compatible smartphone or other smart device can be the receiver. The receiver also stores data on glucose. For a review by the patient and their diabetes health provider, the patient can upload the glucose data. Making judgments regarding adjustments to their insulin dosages or insulin pump settings using this information will help. Australia has one of the highest incidence rates of Type 1 Diabetes in children, ranking 16th out of 123 countries globally for incidences of Type 1 Diabetes in children. All the initiatives from the Australian government encourage the Continuous Glucose Monitoring Durables market to increase in the forecast period.
Rising diabetes prevalence
According to Diabetes Australia, diabetes is the fastest-growing chronic condition in Australia, increasing faster than other chronic diseases such as heart disease and cancer.Currently, almost 1.9 million Australians have diabetes, including all types of diagnosed diabetes (almost 1.5 million known and registered) and undiagnosed type 2 diabetes (up to 500,000 estimated). Around 1.2 million people are hospitalized with diabetes-related conditions every year. Aboriginal and Torres Strait Islander Australians are three times more likely to develop type 2 diabetes than non-indigenous Australians, 4.3 times more likely to be hospitalized with type 2 diabetes, and four times as likely to die from it.
Overall, with rising diabetes prevalence, access to CGM and Flash GM through the NDSS assists in the reduction of the number of severe hypoglycemic events, improvement of glucose management in people with poor glycemic awareness or suboptimal glycemic control (maintaining blood glucose levels in the target range reduces the risks of developing diabetes-related complications) thereby driving the market growth.
Australia Continuous Glucose Monitoring Devices Industry Overview
The Australian continuous glucose monitoring devices market is highly consolidated. The market leaders such as Dexcom, Abbott, and Medtronic focus on product launches and technological collaboration to increase their foothold in the market.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 Market Segmentation
6 Market Indicators
8 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Diabetes Care Inc.
- Dexcom Inc.
- Medtronic PLC
- Eversense
- Ascensia
Methodology
LOADING...
